FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Vaccines miss their mark in seasonal flu campaign

Tools

Each year vaccine makers create a cocktail of antigens designed to stand guard against the various versions of the flu making the rounds in winter. But this year the CDC concludes that most of the influenza B viruses in the U.S. aren't being stopped by the vaccine. Two of the three components in the vaccine aren't aimed the right B targets, it seems. The jab may, though, offer protection against the A versions in circulation.

"Most years, the prediction is very good," Joseph Bresee, an influenza epidemiologist at the CDC, tells the Washington Post. "In 16 of the last 19 years, we have had a well-matched vaccine."

- read the report from the Wall Street Journal

Related Articles:
Universal flu vaccine shows early promise. Report
VaxInnate in a race to produce 'universal' flu vaccine. Report
Flu research points to new delivery technique. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.